Alector Inc (ALEC)

$2.41 -0.02 (-0.82%)
Market Cap 268.18M
Revenue (ttm) 21.05M
Net Income (ttm) -142.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -679.00%
Debt to Equity Ratio 0.32
Volume 320,500
Avg Vol 771,258
Day's Range N/A - N/A
Shares Out 110.36M
Stochastic %K 18%
Beta 0.58
Analysts Sell
Price Target $2.88

Company Profile

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potent...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 231 5660
Address:
131 Oyster Point Boulevard, Suite 600, South San Francisco, United States
manymore
manymore Apr. 22 at 5:55 PM
$ALEC interesting activity
0 · Reply
Pedrogs87
Pedrogs87 Apr. 22 at 5:51 PM
$ALEC
0 · Reply
Pedrogs87
Pedrogs87 Apr. 16 at 9:28 AM
$ALEC https://seekingalpha.com/news/4575281-alector-stock-upgraded-cantor-fitzgerald
0 · Reply
revuelto
revuelto Apr. 15 at 11:25 PM
$ALEC how high can it climb? 🎉
0 · Reply
GSP
GSP Apr. 7 at 9:32 PM
$PTON $ASTC $GVH $ALEC $BFRG
1 · Reply
GSP
GSP Apr. 7 at 9:30 PM
No video tonight, but here is what I'm watching tomorrow: $PTON $ASTC $GVH $ALEC $BFRG
0 · Reply
notreload_ai
notreload_ai Mar. 10 at 2:24 PM
$ALEC $CLRB $DNTH $FSS $HIMS -- THE WSJ
0 · Reply
Nothere2023
Nothere2023 Mar. 10 at 1:47 PM
$ALEC Hold
0 · Reply
Pedrogs87
Pedrogs87 Mar. 10 at 11:50 AM
$ALEC BTIG upgrades Alector with a $6.00 price target. Previous rating adjustments showed downgrades from multiple analysts. Today, Alector (ALEC) received a significant upgrade from BTIG analyst Thomas Shrader. Shrader has moved the rating from 'Neutral' to 'Buy', setting a new price target of $6.00. This change reflects renewed confidence in Alector's market position and potential growth.
0 · Reply
Pedrogs87
Pedrogs87 Mar. 10 at 11:48 AM
$ALEC https://www.investing.com/news/analyst-ratings/alector-stock-rating-upgraded-to-buy-at-btig-on-bbbshuttle-focus-93CH-4551550
0 · Reply
Latest News on ALEC
Alector Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 3:10 PM EST - 7 weeks ago

Alector Transcript: TD Cowen 46th Annual Health Care Conference

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 25, 2026, 4:05 PM EST - 2 months ago

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Alector to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 2 months ago

Alector to Participate in the TD Cowen 46th Annual Health Care Conference

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

Dec 12, 2025, 4:05 PM EST - 4 months ago

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

Alector Transcript: BofA Securities CNS Therapeutics Virtual Conference 2025

Dec 8, 2025, 2:25 PM EST - 4 months ago

Alector Transcript: BofA Securities CNS Therapeutics Virtual Conference 2025

Alector to Participate in the Bank of America CNS Therapeutics Conference

Dec 1, 2025, 4:05 PM EST - 5 months ago

Alector to Participate in the Bank of America CNS Therapeutics Conference

ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

Nov 26, 2025, 11:00 AM EST - 5 months ago

ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 6 months ago

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce

Oct 22, 2025, 12:07 PM EDT - 6 months ago

Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce

Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic

Oct 21, 2025, 6:45 PM EDT - 6 months ago

Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic

Alector shares plunge after dementia drug fails to slow disease progression

Oct 21, 2025, 6:41 PM EDT - 6 months ago

Alector shares plunge after dementia drug fails to slow disease progression

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

Oct 21, 2025, 4:05 PM EDT - 6 months ago

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

Oct 10, 2025, 4:32 AM EDT - 7 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX BDTX CHRS

Alector Transcript: Study Update

Sep 22, 2025, 12:00 PM EDT - 7 months ago

Alector Transcript: Study Update

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

Sep 16, 2025, 8:00 AM EDT - 7 months ago

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

Alector Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 1:30 PM EDT - 8 months ago

Alector Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Alector Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 10:00 AM EDT - 8 months ago

Alector Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Alector Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 3:55 PM EDT - 8 months ago

Alector Transcript: Cantor Global Healthcare Conference 2025

Alector to Participate in Upcoming Healthcare Conferences

Aug 28, 2025, 8:00 AM EDT - 8 months ago

Alector to Participate in Upcoming Healthcare Conferences

Alector Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Alector Earnings Call Transcript: Q2 2025

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

Jul 31, 2025, 4:05 PM EDT - 9 months ago

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

Alector Provides Executive Leadership Update

Jun 13, 2025, 4:05 PM EDT - 11 months ago

Alector Provides Executive Leadership Update

Alector Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 10, 2025, 8:40 AM EDT - 11 months ago

Alector Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 8:00 AM EDT - 11 months ago

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Alector Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 12:00 PM EDT - 1 year ago

Alector Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Alector Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 5:20 PM EDT - 1 year ago

Alector Transcript: BofA Securities 2025 Healthcare Conference

Alector Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Alector Reports First Quarter 2025 Financial Results and Provides Business Update

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

GSK

Alector Transcript: Virtual CNS Forum

Mar 18, 2025, 2:00 PM EDT - 1 year ago

Alector Transcript: Virtual CNS Forum

Alector Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 8:40 AM EDT - 1 year ago

Alector Transcript: Leerink Global Healthcare Conference 2025

Alector Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:10 AM EST - 1 year ago

Alector Transcript: TD Cowen 45th Annual Healthcare Conference

Alector Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Alector Earnings Call Transcript: Q4 2024

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 26, 2025, 4:05 PM EST - 1 year ago

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Feb 19, 2025, 4:05 PM EST - 1 year ago

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Jan 13, 2025, 8:00 AM EST - 1 year ago

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Dec 4, 2024, 2:20 PM EST - 1 year ago

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Nov 26, 2024, 10:29 AM EST - 1 year ago

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Nov 25, 2024, 4:05 PM EST - 1 year ago

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Nov 14, 2024, 4:05 PM EST - 1 year ago

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:05 PM EST - 1 year ago

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Alector Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 9:45 AM EDT - 1 year ago

Alector Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Alector Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 10:00 AM EDT - 1 year ago

Alector Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Alector Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 7:45 AM EDT - 1 year ago

Alector Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Alector Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Alector Earnings Call Transcript: Q2 2024

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Alector to Host Mid-Year Earnings Conference Call

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Alector to Host Mid-Year Earnings Conference Call

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Jul 28, 2024, 8:05 AM EDT - 1 year ago

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Alector Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 27, 2024, 7:00 AM EDT - 1 year ago

Alector Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Alector Transcript: Status Update

Jun 18, 2024, 3:00 PM EDT - 2 years ago

Alector Transcript: Status Update

Alector Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 1:20 PM EDT - 2 years ago

Alector Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Jun 10, 2024, 7:00 AM EDT - 2 years ago

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Alector Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 20, 2024, 11:00 AM EDT - 2 years ago

Alector Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Alector Transcript: BofA Securities 2024 Health Care Conference

May 14, 2024, 11:55 AM EDT - 2 years ago

Alector Transcript: BofA Securities 2024 Health Care Conference

Alector Transcript: Stifel Virtual 2024 CNS Day

Mar 19, 2024, 11:30 AM EDT - 2 years ago

Alector Transcript: Stifel Virtual 2024 CNS Day

Alector Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 13, 2024, 2:05 PM EDT - 2 years ago

Alector Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Alector Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 12, 2024, 10:40 AM EDT - 2 years ago

Alector Transcript: Leerink Partners Global Biopharma Conference 2024

Alector Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 5, 2024, 10:30 AM EST - 2 years ago

Alector Transcript: TD Cowen 44th Annual Health Care Conference 2024

Alector Earnings Call Transcript: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

Alector Earnings Call Transcript: Q4 2023

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 4:05 PM EST - 2 years ago

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Feb 20, 2024, 4:05 PM EST - 2 years ago

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

Feb 8, 2024, 7:00 AM EST - 2 years ago

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Feb 7, 2024, 7:00 AM EST - 2 years ago

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Alector Announces Closing of Public Offering

Jan 19, 2024, 9:20 AM EST - 2 years ago

Alector Announces Closing of Public Offering

Alector Announces Pricing of Public Offering of Common Stock

Jan 17, 2024, 8:54 AM EST - 2 years ago

Alector Announces Pricing of Public Offering of Common Stock

Alector Announces Proposed Public Offering of Common Stock

Jan 16, 2024, 4:01 PM EST - 2 years ago

Alector Announces Proposed Public Offering of Common Stock

Alector Transcript: Status Update

Dec 13, 2023, 11:00 AM EST - 2 years ago

Alector Transcript: Status Update

Alector Transcript: Status Update

Dec 7, 2023, 12:00 PM EST - 2 years ago

Alector Transcript: Status Update

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Nov 28, 2023, 7:00 AM EST - 2 years ago

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Alector to Participate in the Stifel Healthcare Conference

Nov 8, 2023, 7:00 AM EST - 2 years ago

Alector to Participate in the Stifel Healthcare Conference

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 4:05 PM EST - 2 years ago

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Oct 27, 2023, 7:00 AM EDT - 2 years ago

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Alector Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 11, 2023, 4:55 PM EDT - 2 years ago

Alector Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Alector Earnings Call Transcript: Q2 2023

Aug 3, 2023, 4:30 PM EDT - 2 years ago

Alector Earnings Call Transcript: Q2 2023

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Jun 6, 2023, 7:00 AM EDT - 3 years ago

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Alector Reports First Quarter 2023 Financial Results and Provides Business Update

May 4, 2023, 4:05 PM EDT - 3 years ago

Alector Reports First Quarter 2023 Financial Results and Provides Business Update

Alector to Participate in the BofA Securities 2023 Healthcare Conference

May 2, 2023, 7:00 AM EDT - 3 years ago

Alector to Participate in the BofA Securities 2023 Healthcare Conference

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 28, 2023, 4:05 PM EST - 3 years ago

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 8, 2022, 4:30 PM EST - 3 years ago

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Alector Transcript: Status Update

Jul 11, 2022, 7:31 PM EDT - 4 years ago

Alector Transcript: Status Update

Alector Transcript: Collaboration Announcement

Jul 2, 2021, 9:48 AM EDT - 5 years ago

Alector Transcript: Collaboration Announcement

manymore
manymore Apr. 22 at 5:55 PM
$ALEC interesting activity
0 · Reply
Pedrogs87
Pedrogs87 Apr. 22 at 5:51 PM
$ALEC
0 · Reply
Pedrogs87
Pedrogs87 Apr. 16 at 9:28 AM
$ALEC https://seekingalpha.com/news/4575281-alector-stock-upgraded-cantor-fitzgerald
0 · Reply
revuelto
revuelto Apr. 15 at 11:25 PM
$ALEC how high can it climb? 🎉
0 · Reply
GSP
GSP Apr. 7 at 9:32 PM
$PTON $ASTC $GVH $ALEC $BFRG
1 · Reply
GSP
GSP Apr. 7 at 9:30 PM
No video tonight, but here is what I'm watching tomorrow: $PTON $ASTC $GVH $ALEC $BFRG
0 · Reply
notreload_ai
notreload_ai Mar. 10 at 2:24 PM
$ALEC $CLRB $DNTH $FSS $HIMS -- THE WSJ
0 · Reply
Nothere2023
Nothere2023 Mar. 10 at 1:47 PM
$ALEC Hold
0 · Reply
Pedrogs87
Pedrogs87 Mar. 10 at 11:50 AM
$ALEC BTIG upgrades Alector with a $6.00 price target. Previous rating adjustments showed downgrades from multiple analysts. Today, Alector (ALEC) received a significant upgrade from BTIG analyst Thomas Shrader. Shrader has moved the rating from 'Neutral' to 'Buy', setting a new price target of $6.00. This change reflects renewed confidence in Alector's market position and potential growth.
0 · Reply
Pedrogs87
Pedrogs87 Mar. 10 at 11:48 AM
$ALEC https://www.investing.com/news/analyst-ratings/alector-stock-rating-upgraded-to-buy-at-btig-on-bbbshuttle-focus-93CH-4551550
0 · Reply
Nothere2023
Nothere2023 Mar. 9 at 3:46 PM
$ALEC Break 2.5 for 3 💪👍🚀🚀
0 · Reply
Nothere2023
Nothere2023 Mar. 9 at 2:57 PM
$ALEC rally starts
0 · Reply
Pedrogs87
Pedrogs87 Mar. 9 at 2:56 PM
$ALEC
0 · Reply
Nothere2023
Nothere2023 Mar. 6 at 3:20 PM
$ALEC Tbis should rocket back by next week !! No worries Excellent set up !!
0 · Reply
Fringe
Fringe Mar. 5 at 8:58 PM
$ALEC how low does it drop this time?
0 · Reply
Nothere2023
Nothere2023 Mar. 5 at 8:05 PM
$ALEC This looks like good price to get in ?
0 · Reply
Fringe
Fringe Mar. 2 at 2:52 PM
$ALEC back to $2 Run is over just like that.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 9:09 PM
$ALEC RSI: 74.74, MACD: 0.1490 Vol: 0.20, MA20: 2.04, MA50: 1.83 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
revuelto
revuelto Feb. 26 at 7:27 PM
$ALEC buy the…✌️
0 · Reply
Crowbar20
Crowbar20 Feb. 26 at 6:13 PM
$ALEC beast. This was $2.12 at open! Lets get over $2.50 and run.
0 · Reply
Pedrogs87
Pedrogs87 Feb. 25 at 10:17 PM
$ALEC https://www.stocktitan.net/sec-filings/ALEC/10-k-alector-inc-files-annual-report-2226abbd5376.html
0 · Reply
Pedrogs87
Pedrogs87 Feb. 25 at 10:16 PM
$ALEC https://www.sec.gov/ix?doc=/Archives/edgar/data/1653087/000119312526071557/alec-20260225.htm
0 · Reply